Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2013 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.47%

Alnylam Pharmaceuticals reported a smaller-than-expected loss per share, which led to a slight increase in their stock price. The positive EPS surprise suggests that the company is managing expenses effectively, even though revenue details were not disclosed. Investors may view this as a sign of potential future growth, but the lack of guidance leaves some uncertainty.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	-$0.15	N/A	+51.61%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management conveyed a cautious optimism regarding the company's ongoing projects. They emphasized the importance of their pipeline while not providing specific revenue guidance.

Management highlighted progress in their pipeline despite the lack of revenue guidance.

They expressed confidence in future developments but acknowledged challenges ahead.

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.47%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.47%

Key numbers

Management commentary